MUSC Leads State in Biomedical Research Funding

Contact: Heather Woolwine

Sept. 15, 2016

CHARLESTON, SC – The Medical University of South Carolina (MUSC) continues to lead the state in biomedical research with more than $259 million in grant support from outside sources, including more than $109 million from the National Institutes of Health (NIH).

In addition to increases in federally funded research, MUSC noted marked increases in corporate-sponsored research since 2014, with this year’s total at more than $70 million.

"This year, our total extramural grant funding topped more than $250 million for the first time in MUSC's history,” said Kathleen Brady, M.D., Ph.D., MUSC vice president of research. “The projects funded range from innovative nanoparticle approaches and drug delivery to broad outreach campaigns designed to build healthier communities and determine the best approaches to reach rural and underserved communities with state-of-the-art medical treatment. This is a testimony to the excellence, innovation and hard work of the MUSC research community and its dedication to the health of South Carolina and the nation."

Interesting ongoing research at MUSC includes:

Researchers are cautiously optimistic about a brain cancer treatment involving a virus being tested at the MUSC Hollings Cancer Center. Neuro-oncologist David Cachia, M.D., said he doesn’t want to raise false hope, but he is fascinated by the possibilities.
Researchers harness power of viruses to fight cancer

SmartState Center of Economic Excellence AT&T Distinguished Endowed Chair in Cancer Equity and Department of Psychiatry and Behavioral Sciences professor, Chanita Hughes-Halbert, Ph.D., serves as the contact principal investigator for the MUSC Transdisciplinary Collaborative Center. Hughes-Halbert is also program leader for the Cancer Control Research Program at the Hollings Cancer Center, and is an expert in cancer prevention and control, minority health, and developing and implementing health interventions into clinical and community settings.

Great discoveries do come in small packages. Few know that better than Ann-Marie Broome, Ph.D., who feels nanotechnology holds the future of medicine with its ability to deliver powerful drugs in tiny, designer packages. Her latest research finds the perfect application: targeting cancerous brain tumor cells. Results from her recent paper published online in the international journal Nanomedicine – Future Medicine found that a lipid nanocarrier engineered to be small enough to get past the blood-brain barrier could be targeted to deliver a chemotherapeutic drug more efficiently to tumor cells in the brain

For more in-depth information about MUSC’s research and programs, visit Research.

About MUSC

Founded in 1824, the Medical University of South Carolina (MUSC) continues the tradition of excellence in education, research and patient care. MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges and has more than 17,000 employees. As the state’s only integrated academic health sciences center and largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $3.2 billion, with an annual economic impact of nearly $4 billion and annual research funding in excess of $284 million.

As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2019, for the fifth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina.